A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Targeted therapy options for T-cell malignancies are limited.
• Chimeric antigen receptor (CAR) T-cell therapy has shown success against B-cell lymphoid malignancies.
• T-cell neoplasms present unique challenges for CAR T-cell therapy due to antigen overlap with normal T cells.

Purpose of the Study:

• To investigate the efficacy and safety of CAR T cells targeting CD5 for T-cell malignancies.
• To evaluate the potential for fratricide and long-term expansion of CD5 CAR T cells.
• To assess the therapeutic potential of CD5 CAR T cells in preclinical models of T-cell acute lymphoblastic leukemia (T-ALL).

Main Methods:

• Engineering T cells to express a CAR targeting CD5, a pan-T-cell marker.
• Assessing CD5 CAR T-cell fratricide and ex vivo expansion.
• Evaluating the in vitro efficacy against T-ALL and T-cell lymphoma cell lines.
• Testing the in vivo efficacy in xenograft mouse models of T-ALL.

Main Results:

• CD5 CAR T cells exhibited limited fratricide and could be expanded long-term ex vivo.
• CD5 CAR T cells demonstrated effective elimination of malignant T-cell lines in vitro.
• Significant inhibition of disease progression was observed in T-ALL xenograft mouse models.
• The engineered T cells showed therapeutic potential against T-cell neoplasms.

Conclusions:

• CD5 CAR T cells represent a promising therapeutic strategy for T-cell malignancies.
• Targeting CD5 offers a viable approach to overcome challenges in CAR T-cell therapy for T-cell neoplasms.
• Further clinical investigation of CD5 CAR T cells is warranted for patients with T-cell malignancies.